Bioconjugated Liquid-Like Solid Enhances Characterization of Solid Tumor - Chimeric Antigen Receptor T Cell Interactions.

[1]  S. Phillpot,et al.  Bioconjugation of COL1 protein on liquid-like solid surfaces to study tumor invasion dynamics , 2023, Biointerphases.

[2]  E. McGhee,et al.  In situ 3D spatiotemporal measurement of soluble biomarkers in spheroid culture , 2022, In vitro models.

[3]  Snehit Prabhu,et al.  Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium , 2022, Blood advances.

[4]  R. Houot,et al.  Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Elias Sayour,et al.  CAR T Cell Locomotion in Solid Tumor Microenvironment , 2022, Cells.

[6]  J. Urueña,et al.  3D In Vitro Platform for Cell and Explant Culture in Liquid-like Solids , 2022, Cells.

[7]  N. Shah,et al.  Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions , 2022, Frontiers in Immunology.

[8]  J. Drake,et al.  Effects of immune checkpoint blockade on antigen‐specific CD8+ T cells for use in adoptive cellular therapy , 2022, Microbiology and immunology.

[9]  Mariella G. Filbin,et al.  GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas , 2022, Nature.

[10]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[11]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[12]  D. van Noort,et al.  3D hanging spheroid plate for high-throughput CAR T cell cytotoxicity assay , 2021, Journal of Nanobiotechnology.

[13]  F. Klironomos,et al.  A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization , 2021, Frontiers in Immunology.

[14]  S. Jagannath,et al.  Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study , 2021, The Lancet.

[15]  Bethany Bareham,et al.  Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies , 2021, Cancer Immunology, Immunotherapy.

[16]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[17]  C. Rooney,et al.  CD70-specific CAR T-cells have potent activity against Acute Myeloid Leukemia (AML) without HSC toxicity. , 2021, Blood.

[18]  M. Chartrand,et al.  CAR T cells in solid tumors: challenges and opportunities , 2021, Stem Cell Research & Therapy.

[19]  G. Coukos,et al.  Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression , 2020, The Journal of experimental medicine.

[20]  P. Lambin,et al.  A novel co-culture assay to assess anti-tumor CD8+ T cell cytotoxicity via luminescence and multicolor flow cytometry. , 2020, Journal of immunological methods.

[21]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[22]  A. Grippin,et al.  Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas , 2020, Clinical Cancer Research.

[23]  W. Murphy,et al.  Synthetic alternatives to Matrigel , 2020, Nature Reviews Materials.

[24]  Paolo P. Provenzano,et al.  Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments , 2020, Nature Communications.

[25]  G. Ming,et al.  Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing , 2020, Nature Protocols.

[26]  Yong Teng,et al.  Is It Time to Start Transitioning From 2D to 3D Cell Culture? , 2020, Frontiers in Molecular Biosciences.

[27]  Arjun K Menta,et al.  Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? , 2020, Trends in cancer.

[28]  Howard Y. Chang,et al.  CRISPR-engineered T cells in patients with refractory cancer , 2020, Science.

[29]  Marius Pachitariu,et al.  Cellpose: a generalist algorithm for cellular segmentation , 2020, Nature Methods.

[30]  R. Rockne,et al.  Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data , 2020, Journal of the Royal Society Interface.

[31]  S. Tu,et al.  CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma , 2019, Front. Oncol..

[32]  Y. Tabata,et al.  A cancer invasion model combined with CAF aggregates incorporating GM containing a p53 inhibitor. , 2019, Tissue engineering. Part C, Methods.

[33]  Mehmet Toner,et al.  Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned Tumor Arrays , 2019, Advanced science.

[34]  H. Einsele,et al.  ROR1-CAR T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. , 2019, JCI insight.

[35]  F. Bova,et al.  CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors , 2019, Nature Communications.

[36]  Michael Sixt,et al.  Mechanisms of 3D cell migration , 2019, Nature Reviews Molecular Cell Biology.

[37]  H. Farin,et al.  3D model for CAR‐mediated cytotoxicity using patient‐derived colorectal cancer organoids , 2019, The EMBO journal.

[38]  P. Bousso,et al.  Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity , 2019, The Journal of experimental medicine.

[39]  Keyue Shen,et al.  Evaluating CAR‐T Cell Therapy in a Hypoxic 3D Tumor Model , 2019, Advanced healthcare materials.

[40]  Yongxia Wu,et al.  Modelling CAR-T therapy in humanized mice , 2019, EBioMedicine.

[41]  L. Grøntved,et al.  Collagen density regulates the activity of tumor-infiltrating T cells , 2018, Journal of Immunotherapy for Cancer.

[42]  S. Wälchli,et al.  A Spheroid Killing Assay by CAR T Cells. , 2018, Journal of visualized experiments : JoVE.

[43]  Amy McKee,et al.  FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma , 2018, Clinical Cancer Research.

[44]  Ke Liu,et al.  FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia , 2018, Clinical Cancer Research.

[45]  Garima Agrawal,et al.  Stimuli-Responsive Microgels and Microgel-Based Systems: Advances in the Exploitation of Microgel Colloidal Properties and Their Interfacial Activity , 2018, Polymers.

[46]  W. Luyten,et al.  Three‐dimensional cell culture models for anticancer drug screening: Worth the effort? , 2018, Journal of cellular physiology.

[47]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[48]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[49]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[50]  J. Yang,et al.  CD70, a novel target of CAR T-cell therapy for gliomas , 2018, Neuro-oncology.

[51]  M. Kahn,et al.  Development and characterization of a novel luciferase based cytotoxicity assay , 2018, Scientific Reports.

[52]  D. Lu,et al.  Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM , 2017, International journal of cancer.

[53]  S. Fulda,et al.  Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children , 2017, Oncotarget.

[54]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[55]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[56]  Jf Yang,et al.  High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients , 2017, Leukemia.

[57]  Walter Richtering,et al.  Functional Microgels and Microgel Systems. , 2017, Accounts of chemical research.

[58]  Jos Jonkers,et al.  Genetically engineered mouse models in oncology research and cancer medicine , 2016, EMBO molecular medicine.

[59]  J. Yang,et al.  Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers , 2016, Clinical Cancer Research.

[60]  W. Gregory Sawyer,et al.  Liquid-like Solids Support Cells in 3D. , 2016, ACS biomaterials science & engineering.

[61]  J. Burdick,et al.  A practical guide to hydrogels for cell culture , 2016, Nature Methods.

[62]  K. Odunsi,et al.  Non-redundant Requirement for CXCR3 Signaling during Tumoricidal T Cell Trafficking across Tumor Vascular Checkpoints , 2015, Nature Communications.

[63]  D. Hutmacher,et al.  Concise Review: Humanized Models of Tumor Immunology in the 21st Century: Convergence of Cancer Research and Tissue Engineering , 2015, Stem cells.

[64]  M. Schilham,et al.  Expression of the immune regulation antigen CD70 in osteosarcoma , 2015, Cancer Cell International.

[65]  R. McLendon,et al.  Tetanus toxoid and CCL3 improve DC vaccines in mice and glioblastoma patients , 2015, Nature.

[66]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[67]  D. Ingber,et al.  Microfluidic organs-on-chips , 2014, Nature Biotechnology.

[68]  D. Dolfi,et al.  Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors , 2014, Clinical Cancer Research.

[69]  Laura M. Heiser,et al.  A community effort to assess and improve drug sensitivity prediction algorithms , 2014, Nature Biotechnology.

[70]  J. Rommelaere,et al.  NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells , 2013, BMC Cancer.

[71]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[72]  Hao Liu,et al.  T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. , 2011, Blood.

[73]  Wei Zhang,et al.  Mouse models for cancer research , 2011, Chinese journal of cancer.

[74]  Anil K Sood,et al.  Impact of stress on cancer metastasis. , 2010, Future oncology.

[75]  D. Lauffenburger,et al.  Migration of tumor cells in 3D matrices is governed by matrix stiffness along with cell-matrix adhesion and proteolysis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[76]  M. Burdick,et al.  CXCR3/CXCR3 Ligand Biological Axis Impairs RENCA Tumor Growth by a Mechanism of Immunoangiostasis1 , 2006, The Journal of Immunology.

[77]  M. V. D. van den Brink,et al.  CCR2 is required for CD8-induced graft-versus-host disease. , 2005, Blood.

[78]  H. Kleinman,et al.  Matrigel: basement membrane matrix with biological activity. , 2005, Seminars in cancer biology.

[79]  L. D. Pillis,et al.  A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth , 2005 .

[80]  A. Mackensen,et al.  The flow cytometric PKH-26 assay for the determination of T-cell mediated cytotoxic activity. , 2003, Methods.

[81]  T. Schumacher,et al.  CD27 is required for generation and long-term maintenance of T cell immunity , 2000, Nature Immunology.

[82]  E. Saksela,et al.  A simplified isotope release assay for cell-mediated cytotoxicity against anchorage dependent target cells. , 1977, Journal of immunological methods.